Acetaminophen adducts and methods of use thereof
First Claim
1. A method of treating acetaminophen-induced toxicity in a subject in need thereof, the method comprising:
- a) obtaining a biological sample from the subject;
b) measuring the amount of acetaminophen (APAP)-protein adduct in the sample by detecting one or more APAP-protein adducts, wherein each APAP-protein adduct comprises a protein covalently modified with N-acetyl-p-benzoquinone (NAPQI), and wherein the protein is selected from the group consisting of betaine-homocysteine S-methyltransferase 1, cytoplasmic aspartate aminotransferase, 1,4-alpha-glucan-branching enzyme, formimidoyltransferase-cyclodeaminase, and dystrophin;
c) comparing the measured amount of the acetaminophen-protein adduct in the sample to a reference value, wherein a greater amount of acetaminophen-protein adduct in the sample compared to the reference value indicates acetaminophen-induced toxicity in the subject; and
d) administering treatment for acetaminophen-induced toxicity after step c) to the subject.
3 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure relates to acetaminophen protein adducts and methods of diagnosing acetaminophen toxicity using the acetaminophen protein adducts. The present disclosure provides acetaminophen (APAP)-protein adducts and methods of detecting acetaminophen-induced toxicity in a subject using APAP-protein adducts. One aspect of the present disclosure provides an APAP-protein adduct for diagnosing acetaminophen-induced toxicity. According to the present disclosure, the inventors have identified proteins that are modified by N-acetyl-pbenzoquinoneimine (NAPQI) in subjects with acetaminophen-induced toxicity. Non-limiting examples of proteins modified by NAPQI include betaine-homocysteine S-methyltransferase 1, cytoplasmic aspartate aminotransferase, 1,4-alpha-glucan branching enzyme, formimidoyltransferase-cyclodeaminase, and dystrophin.
-
Citations
6 Claims
-
1. A method of treating acetaminophen-induced toxicity in a subject in need thereof, the method comprising:
-
a) obtaining a biological sample from the subject; b) measuring the amount of acetaminophen (APAP)-protein adduct in the sample by detecting one or more APAP-protein adducts, wherein each APAP-protein adduct comprises a protein covalently modified with N-acetyl-p-benzoquinone (NAPQI), and wherein the protein is selected from the group consisting of betaine-homocysteine S-methyltransferase 1, cytoplasmic aspartate aminotransferase, 1,4-alpha-glucan-branching enzyme, formimidoyltransferase-cyclodeaminase, and dystrophin; c) comparing the measured amount of the acetaminophen-protein adduct in the sample to a reference value, wherein a greater amount of acetaminophen-protein adduct in the sample compared to the reference value indicates acetaminophen-induced toxicity in the subject; and d) administering treatment for acetaminophen-induced toxicity after step c) to the subject. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method of treating acetaminophen-induced toxicity in a subject in need thereof, the method comprising:
-
a) obtaining a sample from the subject; b) measuring the amount of acetaminophen (APAP)-protein adduct in the sample to determine a profile of APAP-protein adducts in the subject, the profile comprising the identity and concentration in the sample from the subject of one or more APAP-protein adducts, wherein each APAP-protein adduct comprises a protein covalently modified with N-acetyl-p-benzoquinone (NAPQI), and wherein the protein is selected from the group consisting of betaine-homocysteine S-methyltransferase 1, cytoplasmic aspartate aminotransferase, 1,4-alpha-glucan-branching enzyme, formimidoyltransferase-cyclodeaminase, and dystrophin; c) comparing the profile determined in (b) to a database comprising the presence and concentration of one or more APAP-protein adducts correlated with acetaminophen toxicity; d) identifying a matching entry of the database in which the identity and concentration of the one or more APAP-protein adducts matches the identity and concentration of the one or more APAP-protein adducts in the sample; e) determining the acetaminophen toxicity comprising the particular acetaminophen toxicity of the matching entry; and f) administering treatment for acetaminophen-induced toxicity after step e) to the subject.
-
Specification